Simplicity Solutions LLC Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Simplicity Solutions LLC lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 24.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,349 shares of the company’s stock after selling 1,062 shares during the period. Simplicity Solutions LLC’s holdings in Moderna were worth $333,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cim Investment Management Inc. increased its stake in Moderna by 4.2% in the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after purchasing an additional 86 shares during the period. Cetera Advisor Networks LLC increased its stake in Moderna by 0.5% in the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after purchasing an additional 87 shares during the period. Ancora Advisors LLC increased its stake in Moderna by 41.2% in the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after purchasing an additional 96 shares during the period. Sunbelt Securities Inc. increased its stake in Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after purchasing an additional 100 shares during the period. Finally, Allworth Financial LP increased its stake in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of several research reports. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price target on shares of Moderna in a research note on Thursday, March 28th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a research note on Tuesday, January 2nd. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $126.49.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares in the company, valued at approximately $809,235.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Shannon Thyme Klinger sold 670 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now owns 8,557 shares in the company, valued at $809,235.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the completion of the sale, the director now owns 2,056,931 shares in the company, valued at approximately $212,645,526.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,954 shares of company stock worth $11,533,976. 15.70% of the stock is owned by corporate insiders.

Moderna Trading Down 0.6 %

Shares of Moderna stock opened at $101.41 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $144.43. The firm’s 50 day simple moving average is $100.63 and its two-hundred day simple moving average is $93.64.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the prior year, the business posted $3.61 EPS. Moderna’s revenue for the quarter was down 44.9% compared to the same quarter last year. As a group, analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.